Evidence map›Paper›PMID 28451393›Full record

ArticleBiomedical reports2017

The circulating microRNA-200 family in whole blood are potential biomarkers for high-grade serous epithelial ovarian cancer.

Adam Pendlebury, Natalie J Hannan, Natalie Binder, Sally Beard, Monica Mcgauran, Peter Grant, Stephen Tong, Clare L Whitehead

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biomedical reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. Review
  16. Article
  17. Serum Biomarker Based Algorithms in Diagnosis of Ovarian Cancer: A Review.Indian journal of clinical biochemistry : IJCB · 2018
    Review
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Adam PendleburyDepartment of Gynaecological Oncology, University of Melbourne, Mercy Hospital for Women, Heidelberg, Vic 3084, Australia.
Natalie J HannanDepartment of Obstetrics and Gynaecology, University of Melbourne, Mercy Hospital for Women, Heidelberg, Vic 3084, Australia.
Natalie BinderDepartment of Obstetrics and Gynaecology, University of Melbourne, Mercy Hospital for Women, Heidelberg, Vic 3084, Australia.
Sally BeardDepartment of Obstetrics and Gynaecology, University of Melbourne, Mercy Hospital for Women, Heidelberg, Vic 3084, Australia.
Monica McgauranDepartment of Obstetrics and Gynaecology, University of Melbourne, Mercy Hospital for Women, Heidelberg, Vic 3084, Australia.
Peter GrantDepartment of Gynaecological Oncology, University of Melbourne, Mercy Hospital for Women, Heidelberg, Vic 3084, Australia.
Stephen TongDepartment of Obstetrics and Gynaecology, University of Melbourne, Mercy Hospital for Women, Heidelberg, Vic 3084, Australia.
Clare L WhiteheadDepartment of Obstetrics and Gynaecology, University of Melbourne, Mercy Hospital for Women, Heidelberg, Vic 3084, Australia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Epithelial ovarian cancer (EOC) is the leading cause of mortality with regard to gynaecological cancer. There is no effective biomarker and therefore prognosis is poor as the majority of cases are not diagnosed until advanced disease is present. MicroRNAs (miRs) are dysregulated in ovarian cancer tissue and are present in the circulation. The aim of the present study was to investigate whether circulating miRs from the miR-200 family served as potential candidate biomarkers for the early detection of EOC. Whole blood and ovarian tissue were collected from women with early (stage I/II, n=4), advanced EOC (stage III/IV, n=4), and women with benign ovarian masses (n=5). A panel of 5 miRs were studied in whole blood and ovarian tissue using Taqman RT-PCR miR assays. The expression of circulating miR-200a, miR-200b and miR-200c were upregulated (P<0.05) in ovarian cancer compared to controls, correlated with the stage of disease and reflected tissue expression. Despite a trend, there was no significant increase in the expression of miR-21 and miR-210 in the present study. In conclusion, the circulating miR-200 family may be promising candidate biomarkers for EOC that require validation in a larger study.

Indexed as

biomarkerepithelial ovarian cancermicroRNA

Identifiers

PMID28451393
PMCPMC5403187

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.